Almost guaranteed is the likelihood of Galidesivir being fast-tracked for approval and stockpiling, based on several factors that make its use in addressing viral threats highly probable. It's got broad antiviral activity across multiple viruses, which is critical for its potential stockpiling and use across various viral threats (e.g., Marburg, Ebola, Zika, etc.).
1 - Marburg has a fatality rate of over 90%, with no approved therapies or vaccines. Galidesivir has shown 100% survival rates in animal models if administered within 48 hours, making it a prime candidate for emergency approval, especially since Marburg is classified as a Category A bioterrorism agent.
2 - Due to its broad-spectrum antiviral activity and quick viral clearance (14 days), these animal trials can be completed rapidly. Governments are likely to fast-track approval for stockpiling, similar to how the U.S. spent $138 million on Tpoxx for smallpox. recently https://globalbiodefense.com/2023/07/27/smallpox-countermeasures-u-s-awards-138m-to-siga-technologies-for-tpoxx/
3 - $100 million USD stockpiling deal (similar to Tpoxx for smallpox) could push Galidesivir’s valuation to 40-50c per share. With a Priority Review Voucher (PRV), potentially worth $112.5 million AUD, this adds even more value.
ILA Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)